GlassScriptPhysician profile
Julia Mcneice
NPI 1003308222
$5,609.73
in general payments reported to CMS, 2019-2025
31 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.06 · 2020: $125 · 2021: $107 · 2022: $378 · 2023: $545 · 2024: $1,664 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.07 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $683.34 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $532.03 | 2021-2025 | |
| Lilly USA, LLC | $484.70 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $417.47 | 2022-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $396.04 | 2023-2025 | |
| Exact Sciences Corporation | $285.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $269.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.61 | 2022-2025 | Jardiance |
| Eisai INC. | $168.41 | 2024 | |
| Phathom Pharmaceuticals, INC. | $128.10 | 2025 | Voquezna |
| Dexcom, INC. | $126.47 | 2022-2025 | Dexcom G6 Transmitter |
| Intercept Pharmaceuticals, INC. | $125.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $115.92 | 2024-2025 | |
| Glaxosmithkline, LLC. | $95.73 | 2024-2025 | Trelegy Ellipta, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.99 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $62.68 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $42.64 | 2022 | |
| Abbott Laboratories | $36.75 | 2021 | |
| Medtronic, INC. | $35.20 | 2025 | Inceptiv, Intellis Adaptivestim |
| Astellas Pharma US INC | $32.37 | 2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $31.15 | 2021-2023 | Belsomra |
| Gilead Sciences, INC. | $25.35 | 2025 | |
| Daiichi Sankyo INC. | $25.05 | 2024 | Injectafer |
| Corcept Therapeutics | $21.89 | 2024 | Korlym |
| Hikma Pharmaceuticals USA | $20.50 | 2025 | Ryaltris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.46 | 2024 | Xifaxan |
| Dynavax Technologies Corporation | $18.00 | 2022 | |
| Electromed, INC. | $16.34 | 2021 | |
| Phadia US INC. | $16.12 | 2024 | Immunocap |
| Currax Pharmaceuticals LLC | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Mcneice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.